本文選題：信用評(píng)價(jià) + 中小醫(yī)藥企業(yè)��； 參考：《電子科技大學(xué)》2013年碩士論文

【摘要】：隨著社會(huì)經(jīng)濟(jì)的不斷發(fā)展，作為民生類(lèi)基礎(chǔ)性行業(yè)——醫(yī)藥行業(yè)，受關(guān)注程度越來(lái)越高。人們?cè)谠絹?lái)越關(guān)心自身健康的同時(shí)，也更加關(guān)注醫(yī)藥企業(yè)的信用狀況，尤其是中小醫(yī)藥企業(yè)。國(guó)家不斷適時(shí)地出臺(tái)各項(xiàng)規(guī)章制度來(lái)約束和規(guī)范醫(yī)藥市場(chǎng)，銀行與投資者也越來(lái)越關(guān)注新興中小醫(yī)藥企業(yè)的信用狀況，以減少投資風(fēng)險(xiǎn)。目前國(guó)內(nèi)信用評(píng)價(jià)體系陳舊，評(píng)價(jià)方法不夠具體成熟，針對(duì)性與適用性較弱。因此，需要我們改變研究思路，尋找新方法，不斷嘗試引入新興交叉學(xué)科的優(yōu)秀科研成果，結(jié)合我國(guó)具體國(guó)情社情設(shè)計(jì)一套有利于客觀、公平、公正地對(duì)我國(guó)中小醫(yī)藥企業(yè)進(jìn)行信用評(píng)價(jià)的體系和方法，，這對(duì)于規(guī)范醫(yī)藥市場(chǎng)、改善融資環(huán)境，促進(jìn)企業(yè)快速、健康、可持續(xù)發(fā)展有著重要而積極的意義。 我國(guó)中小醫(yī)藥企業(yè)特點(diǎn)：一、我國(guó)醫(yī)藥行業(yè)屬于技術(shù)密集型產(chǎn)業(yè)，對(duì)技術(shù)含量、創(chuàng)新能力和技術(shù)資本投入要求高，具有高門(mén)檻、高投入、高風(fēng)險(xiǎn)、長(zhǎng)周期的特點(diǎn)；二、中小企業(yè)的標(biāo)志是規(guī)模小、不成熟、高速成長(zhǎng)性和不確定性。因此本文結(jié)合兩者特點(diǎn)，設(shè)計(jì)了包含財(cái)務(wù)與非財(cái)務(wù)因素、靜態(tài)與動(dòng)態(tài)指標(biāo)、還款能力與信用歷史狀況相結(jié)合的中小醫(yī)藥企業(yè)信用評(píng)價(jià)指標(biāo)體系，打破了國(guó)內(nèi)信用評(píng)級(jí)機(jī)構(gòu)已有的因素考慮不周全、財(cái)務(wù)信息過(guò)重、無(wú)行業(yè)針對(duì)性、不考慮政策和國(guó)情因素影響的現(xiàn)狀，提高了信用評(píng)價(jià)結(jié)果的可信度和可解釋性。 本文的研究?jī)?nèi)容如下： 首先，本文系統(tǒng)介紹了我國(guó)中小醫(yī)藥企業(yè)、信用風(fēng)險(xiǎn)和灰色系統(tǒng)的研究現(xiàn)狀和理論基礎(chǔ)；其次，本文通過(guò)大量的文獻(xiàn)閱讀、問(wèn)卷調(diào)查和專(zhuān)家學(xué)者訪問(wèn)結(jié)合的方法來(lái)確定我國(guó)中小醫(yī)藥企業(yè)的信用評(píng)價(jià)指標(biāo)體系，在指標(biāo)權(quán)重確定方面，結(jié)合AHP和熵值法，對(duì)已篩選的評(píng)價(jià)指標(biāo)進(jìn)行組合賦權(quán)，使得指標(biāo)權(quán)重既反映了專(zhuān)家主觀經(jīng)驗(yàn)，又反映了數(shù)據(jù)自身特點(diǎn)，從而盡量避免現(xiàn)有指標(biāo)權(quán)重設(shè)計(jì)過(guò)分依賴專(zhuān)家經(jīng)驗(yàn)的不足；再次，依據(jù)我國(guó)中小醫(yī)藥企業(yè)成立時(shí)間短、原始數(shù)據(jù)缺乏、樣本量不足、信息披露不徹底等諸多不確定因素的特點(diǎn)，運(yùn)用灰色系統(tǒng)理論的方法來(lái)評(píng)估中小醫(yī)藥企業(yè)信用狀況是比較恰當(dāng)?shù)�，并且做了�?duì)比分析；最后，對(duì)深交所中小板全部18家中小醫(yī)藥企業(yè)的信用風(fēng)險(xiǎn)進(jìn)行實(shí)證研究，驗(yàn)證了方法的可行性。
[Abstract]:With the continuous development of social economy, as the basic industry of people's livelihood-pharmaceutical industry, the degree of concern is getting higher and higher. People are more and more concerned about their own health, but also pay more attention to the credit status of pharmaceutical enterprises, especially small and medium-sized pharmaceutical enterprises. In order to reduce the investment risk, banks and investors are paying more and more attention to the credit status of the new small and medium-sized pharmaceutical enterprises. At present, the domestic credit evaluation system is old, the evaluation method is not specific and mature, the pertinence and applicability are weak. Therefore, it is necessary for us to change our research ideas, find new methods, constantly try to introduce the outstanding scientific research results of emerging interdisciplinary disciplines, and design a set of scientific research results that are beneficial to objectivity and fairness in the light of the specific conditions of our country. The system and method of credit evaluation for small and medium-sized pharmaceutical enterprises in China are fair, which is of great and positive significance for standardizing the pharmaceutical market, improving the financing environment, promoting the rapid, healthy and sustainable development of the enterprises. The characteristics of small and medium-sized pharmaceutical enterprises in China are as follows: first, the pharmaceutical industry in China is a technology-intensive industry, which requires high technological content, innovation ability and technical capital investment, and has the characteristics of high threshold, high investment, high risk and long period; second, The symbol of small and medium-sized enterprises is small, immature, high-speed growth and uncertainty. Therefore, combining the characteristics of the two, this paper designs a credit evaluation index system for small and medium-sized pharmaceutical enterprises, which includes financial and non-financial factors, static and dynamic indicators, repayment ability and credit history. The existing factors of domestic credit rating agencies are considered insufficiently, the financial information is too heavy, the industry is not targeted, the influence of policy and national factors is not considered, and the credibility and interpretability of the credit evaluation results are improved. The contents of this paper are as follows: First of all, this paper systematically introduces the research status and theoretical basis of the small and medium-sized pharmaceutical enterprises in China, credit risk and grey system; secondly, this paper through a large number of literature reading, The credit evaluation index system of small and medium-sized pharmaceutical enterprises in our country is determined by the methods of questionnaire survey and experts and scholars' visits. In the aspect of determining the index weight, combined with AHP and entropy method, the selected evaluation indexes are combined and weighted. The index weight not only reflects the subjective experience of experts, but also reflects the characteristics of the data itself, so as to avoid the deficiency of the existing index weight design relying too much on expert experience. Thirdly, according to the short time of establishment of small and medium-sized pharmaceutical enterprises in China, The characteristics of many uncertain factors, such as lack of original data, insufficient sample size, incomplete information disclosure, etc., it is more appropriate to use the method of grey system theory to evaluate the credit status of small and medium-sized pharmaceutical enterprises, and make a comparative analysis. An empirical study on the credit risk of all 18 small pharmaceutical enterprises on Shenzhen Stock Exchange is carried out, which verifies the feasibility of the method.
【學(xué)位授予單位】：電子科技大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類(lèi)號(hào)】：F426.72;F276.3;N941.5

【參考文獻(xiàn)】

中國(guó)期刊全文數(shù)據(jù)庫(kù) 前10條

1 施錫銓,鄒新月;典型判別分析在企業(yè)信用風(fēng)險(xiǎn)評(píng)估中的應(yīng)用[J];財(cái)經(jīng)研究;2001年10期

2 張玲,曾維火;基于Z值模型的我國(guó)上市公司信用評(píng)級(jí)研究[J];財(cái)經(jīng)研究;2004年06期

3 朱小宗,張宗益,耿華丹;現(xiàn)代信用風(fēng)險(xiǎn)度量模型剖析與綜合比較分析[J];財(cái)經(jīng)研究;2004年09期

4 王毅春,孫林巖;現(xiàn)代信用風(fēng)險(xiǎn)模型特征比較研究[J];當(dāng)代經(jīng)濟(jì)科學(xué);2004年02期

5 韓靜;;基于概率神經(jīng)網(wǎng)絡(luò)的企業(yè)信用評(píng)級(jí)模型研究[J];工業(yè)技術(shù)經(jīng)濟(jì);2005年09期

6 程鵬,吳沖鋒,李為冰;信用風(fēng)險(xiǎn)度量和管理方法研究[J];管理工程學(xué)報(bào);2002年01期

7 王春峰,萬(wàn)海暉,張維;組合預(yù)測(cè)在商業(yè)銀行信用風(fēng)險(xiǎn)評(píng)估中的應(yīng)用[J];管理工程學(xué)報(bào);1999年01期

8 馬九杰,郭宇輝,朱勇;縣域中小企業(yè)貸款違約行為與信用風(fēng)險(xiǎn)實(shí)證分析[J];管理世界;2004年05期

9 夏紅芳;劉思峰;;企業(yè)信用風(fēng)險(xiǎn)評(píng)判的模糊神經(jīng)網(wǎng)絡(luò)方法[J];華東經(jīng)濟(jì)管理;2006年03期

10 李萌;Logit模型在商業(yè)銀行信用風(fēng)險(xiǎn)評(píng)估中的應(yīng)用研究[J];管理科學(xué);2005年02期

中國(guó)重要會(huì)議論文全文數(shù)據(jù)庫(kù) 前1條

1 劉思峰;J.福雷斯特;;不確定性系統(tǒng)與模型精細(xì)化誤區(qū)[A];第19屆灰色系統(tǒng)全國(guó)會(huì)議論文集[C];2010年

中國(guó)博士學(xué)位論文全文數(shù)據(jù)庫(kù) 前1條

1 孫利國(guó);面向風(fēng)險(xiǎn)投資評(píng)審的科技型中小企業(yè)信用評(píng)價(jià)方法研究[D];天津大學(xué);2012年

中國(guó)碩士學(xué)位論文全文數(shù)據(jù)庫(kù) 前2條

1 安娜;我國(guó)中小醫(yī)藥企業(yè)信用評(píng)級(jí)研究[D];華中科技大學(xué);2006年

2 武慧碩;基于相對(duì)熵—灰色關(guān)聯(lián)的上市中小企業(yè)信用評(píng)價(jià)[D];大連理工大學(xué);2009年

本文編號(hào)：1901046